| Product Name |
α adrenergic receptor |
β adrenergic receptor |
Purity |
| Isoprenaline hydrochloride |
|
|
99.86% |
| Norepinephrine |
α1-adrenergic receptor
α2-adrenergic receptor
|
Beta-1 adrenergic receptor
|
99.43% |
| Propranolol hydrochloride |
|
|
99.96% |
| Zenidolol hydrochloride |
|
|
99.74% |
| Phenylephrine |
|
|
99.94% |
| CL 316243 |
|
|
99.95% |
| D-Mannitol |
|
Beta-3 adrenergic receptor
|
99.93% |
| Propranolol |
|
|
99.87% |
| Phenylephrine hydrochloride |
|
|
99.97% |
| Norepinephrine hydrochloride |
α1-adrenergic receptor
α2-adrenergic receptor
|
Beta-1 adrenergic receptor
|
99.95% |
| Metoprolol |
|
|
99.94% |
| Atenolol |
|
Beta-1 adrenergic receptor, Ki: 697 nM
|
99.94% |
| Clozapine |
α2-adrenergic receptor, Ki: 51 nM (Inhibitor)
|
|
99.97% |
| Prazosin hydrochloride |
|
|
99.86% |
| Dexmedetomidine |
α2-adrenergic receptor, Ki: 1.08 nM
|
|
99.93% |
| Nadolol |
|
|
99.97% |
| Salbutamol |
|
|
99.92% |
| Norepinephrine bitartrate monohydrate |
α1-adrenergic receptor
α2-adrenergic receptor
|
Beta-1 adrenergic receptor
|
99.75% |
| Mirabegron |
|
|
99.90% |
| Dexmedetomidine hydrochloride |
α2-adrenergic receptor, IC50: 1.08 nM
|
|
99.93% |
| Phenylacetylglycine |
|
|
99.63% |
| Salmeterol |
|
β3 adrenoceptor, pEC50: 5.9
β2 adrenoceptor, pEC50: 9.6
β1 adrenoceptor, pEC50: 6.1
|
99.91% |
| (S)-Timolol maleate |
|
|
99.89% |
| SR59230A |
|
|
≥98.0% |
| Vilanterol trifenatate |
|
|
99.61% |
| Dobutamine hydrochloride |
|
|
99.91% |
| Labetalol |
|
|
99.88% |
| Guanfacine hydrochloride |
|
|
99.96% |
| L748337 |
|
Beta-2 adrenergic receptor, Ki: 204 nM
Beta-1 adrenergic receptor, Ki: 390 nM
Beta-3 adrenergic receptor, Ki: 4 nM
|
99.67% |
| Clonidine hydrochloride |
|
|
99.96% |
| Paliperidone |
|
|
99.69% |
| Tamsulosin |
|
|
99.77% |
| SR59230A hydrochloride |
|
|
99.87% |
| Bisoprolol hemifumarate |
|
Beta-1 adrenergic receptor
|
99.73% |
| Doxazosin mesylate |
|
|
98.34% |
| Phentolamine mesylate |
|
|
99.87% |
| Octopamine hydrochloride |
|
|
99.65% |
| Mirtazapine |
α2-adrenergic receptor, pKi: 6.95
|
|
99.94% |
| Indacaterol maleate |
|
|
99.82% |
| Acebutolol hydrochloride |
|
|
99.97% |
| Indacaterol |
|
|
99.98% |
| Vibegron |
|
β3 adrenoceptor, EC50: 1.1 nM
|
98.26% |
| Terbutaline sulfate |
|
|
99.95% |
| Nefazodone hydrochloride |
|
|
99.87% |
| Reboxetine mesylate |
|
|
99.90% |
| Pronethalol |
|
|
99.73% |
| Vilanterol |
|
|
99.30% |
| Naftopidil |
Alpha-1A adrenergic receptor, Ki: 3.7 nM
Alpha-1D adrenergic receptor, Ki: 1.2 nM
Alpha-1B adrenergic receptor, Ki: 20 nM
|
|
98.47% |
| Bufuralol |
|
|
99.17% |
| Fenoterol hydrobromide |
|
|
99.90% |
| Butaxamine hydrochloride |
|
Beta-2 adrenergic receptor
|
99.87% |
| Medetomidine hydrochloride |
α1-adrenergic receptor, Ki: 1750 nM
α2-adrenergic receptor, Ki: 1.08 nM
|
|
99.92% |
| Methyldopa hydrate |
|
|
99.95% |
| Phentolamine |
|
|
99.94% |
| Atipamezole hydrochloride |
|
|
99.97% |
| Penbutolol sulfate |
|
|
98.72% |
| Isoferulic acid |
|
|
99.82% |
| DL-Norepinephrine hydrochloride |
|
|
99.59% |
| Idazoxan hydrochloride |
|
|
99.32% |
| Blonanserin |
α1-adrenergic receptor, Ki: 26.7 (Rat nM
α2-adrenergic receptor, Ki: 530 (Rat c nM
|
|
99.62% |
| JP1302 dihydrochloride |
human α2C-adrenoceptor, Ki: 28±2 nM
rodent α2D-adrenoceptor, Ki: 1700±200 nM
human α2A-adrenoceptor, Ki: 3150±50 nM
human α2B-adrenoceptor, Ki: 1470±130 nM
|
|
99.62% |
| BI-167107 |
|
|
99.98% |
| Terbutaline |
|
Beta-2 adrenergic receptor
|
99.77% |
| Carazolol |
|
β3 adrenoceptor
β2 adrenoceptor
β1 adrenoceptor
|
99.71% |
| Salbutamol hemisulfate |
|
|
≥98.0% |
| Midodrine hydrochloride |
|
|
99.49% |
| Metoprolol succinate |
|
|
99.90% |
| Asenapine |
α1-adrenergic receptor, pKi: 8.9
Alpha-2A adrenergic receptor, pKi: 8.9
Alpha-2C adrenergic receptor, pKi: 8.9
Alpha-2B adrenergic receptor, pKi: 9.5
|
|
99.62% |
| Lubabegron |
|
|
98.21% |
| Levobunolol hydrochloride |
|
|
99.89% |
| Talipexole dihydrochloride |
α2-adrenergic receptor, IC50: 25 nM
|
|
99.80% |
| Brimonidine |
|
|
99.99% |
| Oxprenolol hydrochloride |
|
β-adrenoceptor, Ki: 7.1 nM
|
99.86% |
| Olodaterol |
|
β2 adrenoceptor, EC50: .1 nM
|
98.47% |
| (R)-Propranolol hydrochloride |
|
|
99.36% |
| (S)-(-)-Propranolol hydrochloride |
|
|
99.95% |
| Ecopipam hydrochloride |
Alpha-2A adrenergic receptor, Ki: 731 nM
|
|
99.46% |
| Salmeterol xinafoate |
|
β3 adrenoceptor, pEC50: 5.9
β2 adrenoceptor, pEC50: 9.6
β1 adrenoceptor, pEC50: 6.1
|
99.96% |
| Olodaterol hydrochloride |
|
β2 adrenoceptor, EC50: .1 nM
|
98.87% |
| Medetomidine |
α1-adrenergic receptor, Ki: 1750 nM
α2-adrenergic receptor, Ki: 1.08 nM
|
|
99.99% |
| Harmane |
α2-adrenergic receptor, IC50: 18 μM
|
|
99.91% |
| LY 344864 |
rat α1-adrenergic receptor, Ki: 5.06 μM
rat α2-adrenergic receptor, Ki: 3.69 μM
|
|
98.93% |
| (R)-(+)-Atenolol |
|
|
≥99.0% |
| Methyldopa |
|
|
98.25% |
| Vatinoxan hydrochloride |
|
|
99.89% |
| Practolol |
|
|
99.78% |
| Isoetharine mesylate |
|
|
99.87% |
| Bevantolol hydrochloride |
|
|
98.98% |
| Clorprenaline hydrochloride |
|
|
99.90% |
| Synephrine |
|
|
≥98.0% |
| Xylometazoline hydrochloride |
Alpha-1A adrenergic receptor, Ki: 0.05 μM
Alpha-2A adrenergic receptor, Ki: 0.88 μM
Alpha-2C adrenergic receptor, Ki: 0.19 μM
Alpha-2B adrenergic receptor, Ki: 1.7 μM
Alpha-1D adrenergic receptor, Ki: 0.15 μM
Alpha-1B adrenergic receptor, Ki: 0.30 μM
|
|
99.94% |
| Higenamine |
|
|
98.91% |
| Talinolol |
|
Beta-1 adrenergic receptor
|
99.64% |
| ARC 239 dihydrochloride |
Alpha-2B adrenergic receptor
|
|
99.57% |
| Dapiprazole hydrochloride |
|
|
99.87% |
| NP10679 |
Alpha-1A adrenergic receptor, IC50: 0.154 μM
Alpha-1A adrenergic receptor, Ki: 0.603 μM
Alpha-2C adrenergic receptor, Ki: 3.09 μM
Alpha-1D adrenergic receptor, Ki: 0.495 μM
Alpha-1B adrenergic receptor, Ki: 1.92 μM
|
|
99.42% |
| Metipranolol |
|
β2 adrenoceptor, pA2: 8.4
β1 adrenoceptor, pA2: 8.3
|
98.36% |
| BMY 7378 |
rat alpha1D-adrenergic receptor, Ki: 2 nM
rat α1A-adrenergic receptor, Ki: 800 nM
hamster alpha1B-adrenergic receptor, Ki: 600 nM
|
|
99.92% |
| Desglymidodrine |
α1B-adrenergic receptor, pKi: 5.16
α1A-adrenergic receptor, pKi: 5.89
rat alpha1D-adrenergic receptor, pKi: 5.78
human α2A-adrenoceptor, pKi: 5.83
|
|
|
| Urapidil hydrochloride |
α1-adrenergic receptor, pIC50: 6.13
α2-adrenergic receptor, pIC50: 4.38
|
|
99.97% |
| Metoprolol-d7 hydrochloride |
|
|
99.71% |
| Tamsulosin hydrochloride |
|
|
99.81% |
| (+)-Penbutolol |
|
|
|
| Synephrine hydrochloride |
|
|
99.66% |
| Ro 363 hydrochloride |
|
|
|
| Metoprolol tartrate |
|
|
99.98% |
| Efaroxan hydrochloride |
|
|
99.94% |
| Spiroxatrine |
|
|
99.18% |
| Salmeterol-d3 |
|
|
98.91% |
| BMS-466442 |
α adrenergic receptor, IC50: ≥10 μM
|
|
98.99% |
| BMY-14802 hydrochloride |
|
|
98.02% |
| Abanoquil |
|
|
98.43% |
| (RS)-Butyryltimolol |
|
|
≥98.0% |
| Nifenalol hydrochloride |
|
|
99.93% |
| Methyldopate |
|
|
98.01% |
| Bufuralol hydrochloride |
|
|
≥99.0% |
| Clozapine (Standard) |
|
|
99.98% |
| Tasipimidine sulfate |
human α2C-adrenoceptor, pEC50: 6.29
rodent α2D-adrenoceptor, pEC50: 6.56
human α2A-adrenoceptor, pEC50: 7.57
human α2B-adrenoceptor, pEC50: 6.00
|
|
99.46% |
| Reproterol |
|
|
|
| Mabuterol |
|
Beta-2 adrenergic receptor
|
99.96% |
| A-61603 |
|
|
≥99.0% |
| Arformoterol |
|
Beta-2 adrenergic receptor, Kd: 2.9 nM
|
99.96% |
| Ajmalicine |
α1-adrenergic receptor
α2-adrenergic receptor
|
|
99.39% |
| Ecopipam hydrobromide |
Alpha-2A adrenergic receptor, Ki: 731 nM
|
|
≥99.0% |
| MT-1207 |
α1B-adrenergic receptor, IC50: 0.15 nM
α1B-adrenergic receptor, Ki: 1.40 nM
α1A-adrenergic receptor, IC50: 0.1 nM
α1D-adrenergic receptor, IC50: 0.086 nM
α1D-adrenergic receptor, Ki: 0.69 nM
|
|
99.96% |
| Mibenratide |
|
Beta-1 adrenergic receptor
|
99.77% |
| Alfuzosin hydrochloride |
|
|
99.82% |
| Dicentrine |
|
|
99.38% |
| DL 071IT |
|
|
|
| Norepinephrine tartrate |
α1-adrenergic receptor
α2-adrenergic receptor
|
Beta-1 adrenergic receptor
|
99.45% |
| Celiprolol hydrochloride |
|
β adrenergic receptor, Ki: 0.14-8.3 μM
|
98.93% |
| CGP 12177 hydrochloride |
|
Beta-2 adrenergic receptor
Beta-1 adrenergic receptor
Beta-3 adrenergic receptor
|
99.69% |
| Bisoprolol |
|
Beta-1 adrenergic receptor
|
99.78% |
| Cimaterol |
|
|
99.13% |
| Mirtazapine (Standard) |
|
|
99.95% |
| Bupranolol |
|
|
98.73% |
| ST1936 |
α1-adrenergic receptor, Ki: 390 nM (rat)
α2-adrenergic receptor, Ki: 300 nM (rat)
α2-adrenergic receptor, Ki: 300 nM (human)
|
|
99.70% |
| Metaterol |
|
|
|
| ORM-10921 free base |
Alpha-2C adrenergic receptor, Ki: 1.4 nM
|
|
|
| Metipranolol hydrochloride |
|
|
99.92% |
| Scopine hydrochloride |
|
|
99.69% |
| AGN 192836 |
|
|
99.49% |
| Terbutaline sulfate (Standard) |
|
|
99.95% |
| Bunazosin |
|
|
98.52% |
| Butyryltimolol |
|
|
≥98.0% |
| Prenalterol |
|
|
99.18% |
| Oxyfedrine |
|
|
|
| Brombuterol-d9 |
|
|
≥99.0% |
| Amosulalol |
|
Beta-1 adrenergic receptor
|
98.69% |
| BMY 14802 |
|
|
98.96% |
| HOKU-81 |
|
Beta-2 adrenergic receptor
|
|
| ARC 239 |
human α2C-adrenoceptor, pKi: 6.95
Alpha-2C adrenergic receptor, pKi: 7.06
|
|
99.71% |
| (Rac)-Rotigotine hydrochloride |
Alpha-2B adrenergic receptor
|
|
98.66% |
| MK-761 free base |
|
Beta-2 adrenergic receptor
|
|
| Dopexamine hydrochloride |
|
|
99.71% |
| Midodrine |
|
|
99.67% |
| Cyanopindolol |
|
|
|
| Xylometazoline |
Alpha-1A adrenergic receptor, Ki: 0.05 μM
Alpha-2A adrenergic receptor, Ki: 0.88 μM
Alpha-2C adrenergic receptor, Ki: 0.19 μM
Alpha-2B adrenergic receptor, Ki: 1.7 μM
Alpha-1D adrenergic receptor, Ki: 0.15 μM
Alpha-1B adrenergic receptor, Ki: 0.30 μM
|
|
|
| Isoetharine |
|
|
|
| Timolol |
|
|
|
| Timolol hemihydrate |
|
|
|
| (R,R)-Reboxetine mesylate |
|
|
|
| Sotalol |
|
|
|
| Blonanserin dihydrochloride |
α1-adrenergic receptor, Ki: 26.7 nM
α2-adrenergic receptor, Ki: 530 nM
|
|
|
| Doxazosin-d8 |
|
|
|
| Rec 15/2615 hydrochloride |
α1B-adrenergic receptor, Ki: 0.3 nM
α1A-adrenergic receptor, Ki: 1.9 nM
Alpha-1D adrenergic receptor, Ki: 2.6 nM
|
|
|
| Isamoltane hemifumarate |
|
β-adrenoceptor, IC50: 8.4 nM
|
|
| RS-79948-197 |
human α2C-adrenoceptor, Kd: 0.77 nM
rat α2B recepter, Kd: 0.18 nM
rat α2C recepter, Kd: 0.19 nM
human α2A-adrenoceptor, Kd: 0.6 nM
rat α2A receptor, Kd: 0.42 nM
human α2B-adrenoceptor, Kd: 0.46 nM
|
|
|
| α1A-AR Degrader 9c |
α1A-adrenergic receptor, DC50: 2.86 μM
|
|
|
| Acebutolol |
|
|
|
| S(-)-Bisoprolol fumarate |
|
|
|
| β2AR agonist /M-receptor antagonist-1 |
|
Beta-2 adrenergic receptor
|
|
| Nipradolol |
|
|
|
| Agroclavine |
|
|
|
| Rezatomidine |
|
|
|
| S(-)-Bisoprolol |
|
|
|
| Zolertine hydrochloride |
α1B-adrenergic receptor, pKi: 6.81 (in rat liver membrane)
α1A-adrenergic receptor, pKi: 6.35 (in rabbit liver membrane)
|
|
|
| Cimbuterol-d9 |
|
|
|
| (+)-Sotalol |
|
|
98.82% |
| Ro 70‐0004 |
Alpha-1A adrenergic receptor, pKi: 8.9
|
|
|
| ST91 |
|
|
99.75% |
| Ractopamine |
|
pig β2AR, Kd: ~25 nM
pig β1AR, Kd: ~25 nM
|
|
| Diacetolol-d7 |
|
|
|
| Methyldopate hydrochloride |
|
|
|
| (±)-Penbutolol-d9 hydrochloride |
|
|
|
| α2AR agonist 1 |
|
|
|
| Ajmalicine hydrochloride |
α1-adrenergic receptor
α2-adrenergic receptor
|
|
|
| BODIPY FL prazosin |
α1B-adrenergic receptor, Ki: 43.3 nM
α1A-adrenergic receptor, Ki: 14.5 nM
|
|
|
| SUN-1334H free base |
Alpha-1D adrenergic receptor, IC50: 7.76 μM
|
|
|
| Isoprenaline hemisulfate |
|
|
|
| Trimazosin |
|
|
|
| Phenylethanolamine A-d3 |
|
|
|
| AVN-101 hydrochloride |
Alpha-1A adrenergic receptor, Ki: 18.9 nM
Alpha-2A adrenergic receptor, Ki: 1.77 nM
Alpha-2C adrenergic receptor, Ki: 3.55 nM
Alpha-2B adrenergic receptor, Ki: 0.41 nM
Alpha-1D adrenergic receptor, Ki: 30.2 nM
Alpha-1B adrenergic receptor, Ki: 9.4 nM
|
|
99.59% |
| Asenapine citrate |
α1-adrenergic receptor, pKi: 8.9
Alpha-2A adrenergic receptor, pKi: 8.9
Alpha-2C adrenergic receptor, pKi: 8.9
Alpha-2B adrenergic receptor, pKi: 9.5
|
|
|
| α2C adrenoceptor agonist 1 |
Alpha-2C adrenergic receptor, EC50: 108 nM
Alpha-2C adrenergic receptor, Ki: 12 nM
|
|
|
| JP1302 |
human α2C-adrenoceptor, Ki: 28±2 nM
rodent α2D-adrenoceptor, Ki: 1700±200 nM
human α2A-adrenoceptor, Ki: 3150±50 nM
human α2B-adrenoceptor, Ki: 1470±130 nM
|
|
|
| Fenoterol hydrobromide (Standard) |
|
|
|
| β2AR/M3-receptor agonist-1 |
|
β2 adrenoceptor, pEC50: >9.2
|
|
| Naftopidil hydrochloride |
Alpha-1A adrenergic receptor, Ki: 3.7 nM
Alpha-1D adrenergic receptor, Ki: 1.2 nM
Alpha-1B adrenergic receptor, Ki: 20 nM
|
|
|
| Fluparoxan |
|
|
|
| α2A-AR agonist 1 |
Alpha-1A adrenergic receptor, EC50: 2.5 nM
Alpha-2A adrenergic receptor, EC50: 0.23 nM
Alpha-2C adrenergic receptor, EC50: 21.3 nM
Alpha-2B adrenergic receptor, EC50: 16.3 nM
|
|
|
| Atenolol (Standard) |
|
Beta-1 adrenergic receptor
|
99.94% |
| LAS190792 |
|
β3 adrenoceptor, pIC50: 5.6
β2 adrenoceptor, pIC50: 9.1
β1 adrenoceptor, pIC50: 7.5
|
|
| Metoprolol fumarate |
|
|
|
| Nifenalol |
|
Beta-1 adrenergic receptor
|
|
| Mabuterol hydrochloride |
|
Beta-2 adrenergic receptor
|
|
| Pronethalol hydrochloride |
|
|
|
| Oxprenolol |
|
β-adrenoceptor, Ki: 7.10 nM
|
|
| Naftopidil dihydrochloride |
Alpha-1A adrenergic receptor, Ki: 3.7 nM
Alpha-1D adrenergic receptor, Ki: 1.2
Alpha-1B adrenergic receptor, Ki: 20 nM
|
|
|
| Meluadrine tartrate |
|
|
|
| Metrenperone |
α1-adrenergic receptor
α2-adrenergic receptor
|
|
|
| Bevantolol |
|
Beta-1 adrenergic receptor
|
|
| Acebutolol-d7 |
|
|
|
| Dapiprazole |
|
|
|
| Harmane (Standard) |
|
|
|
| Procaterol |
|
|
|
| (E)-Guanabenz |
|
|
|
| Nemazoline |
α1-adrenergic receptor
α2-adrenergic receptor
|
|
|
| Levobunolol |
|
|
|
| ST1936 oxalate |
α1-adrenergic receptor, Ki: 390 nM (rat)
α2-adrenergic receptor, Ki: 300 nM (rat)
α2-adrenergic receptor, Ki: 300 nM (human)
|
|
|
| SB-206606 |
|
Beta-3 adrenergic receptor
|
|
| TAAR1 agonist 3 |
Alpha-2A adrenergic receptor, pEC50: 6
|
|
|
| CHF-6550 |
|
β2 adrenoceptor, pKi: 10.6
|
|
| Sulfinalol |
|
|
|
| Propranolol-d7 hydrochloride |
|
|
98.02% |
| Levobetaxolol |
|
β3 adrenoceptor, IC50: 709 nM
β2 adrenoceptor, IC50: 2970 nM
β1 adrenoceptor, IC50: 33.2 nM
|
|
| Pafenolol |
|
Beta-1 adrenergic receptor
|
|
| Celiprolol |
|
β adrenergic receptor, Ki: 0.14-8.3 μM
|
|
| L-665871 |
|
|
|
| Amidephrine |
|
|
|
| Bisoprolol fumarate |
|
Beta-1 adrenergic receptor
|
|
| Brombuterol-d9 hydrochloride |
|
|
|
| TD-5471 hydrochloride |
|
|
|
| 2-MPMDQ |
α1-adrenergic receptor, Ki: 0.37 nM
α2-adrenergic receptor, Ki: 1740 nM
|
|
|
| Bopindolol |
|
β2 adrenoceptor
Beta-1 adrenergic receptor
Beta-3 adrenergic receptor
|
|
| 4-Hydroxypropranolol-d7 hydrochloride |
|
|
|
| Undecylenoyl phenylalanine |
|
|
|
| Butaxamine |
|
|
|
| Bopindolol fumarate |
|
β3 adrenoceptor
β2 adrenoceptor
β1 adrenoceptor
|
|
| Mabuterol-d9 |
|
|
|
| Flestolol sulfate |
|
|
|
| Meluadrine |
|
|
|
| Fipamezole |
human α2C-adrenoceptor, Ki: 55 nM
human α2A-adrenoceptor, Ki: 9.2 nM
human α2B-adrenoceptor, Ki: 17 nM
|
|
|
| RWJ52353 |
α1-adrenergic receptor, Ki: 443 nM
Alpha-2D adrenergic receptor, Ki: 1.5 nM
Alpha-2A adrenergic receptor, Ki: 254 nM
Alpha-2B adrenergic receptor, Ki: 621 nM
|
|
|
| Apraclonidine |
|
|
|
| Arformoterol tartrate |
|
Beta-2 adrenergic receptor, Kd: 2.9 nM
|
|
| Ecopipam |
Alpha-2A adrenergic receptor, Ki: 731 nM
|
|
|
| Moprolol |
|
Beta-1 adrenergic receptor
|
|
| Metoprolol-d6 tartrate |
|
|
|
| Delequamine hydrochloride |
α1-adrenergic receptor, pKi: 5.3
α2-adrenergic receptor, pKi: 9.5
|
|
|
| Clenproperol-d7 |
|
|
|
| N-5984 |
|
|
|
| L-Epinephrine sulfate |
|
|
|
| Levalbuterol tartrate |
|
|
|
| SAR-150640 |
|
|
|
| CL 316243 free acid |
|
|
99.37% |
| PF-9404C |
|
|
|
| Arformoterol maleate |
|
Beta-2 adrenergic receptor, Kd: 2.9 nM
|
|
| Trimazosin hydrochloride hydrate |
|
|
|
| Delequamine |
α1-adrenergic receptor, pKi: 5.3
α2-adrenergic receptor, pKi: 9.5
|
|
|
| SB251023 |
|
Beta-3 adrenergic receptor
|
|
| Methyldopa hydrochloride |
|
|
|
| Fiduxosin hydrochloride |
α1B-adrenergic receptor, IC50: 24.9 nM
α1A-adrenergic receptor, IC50: 0.16 nM
α1D-adrenergic receptor, IC50: 0.92 nM
|
|
|
| Indacaterol xinafoate |
|
|
|
| RU 52583 |
|
|
|
| (rac)-Nebivolol-d4 |
|
|
|
| Protokylol hydrochloride |
|
Beta-2 adrenergic receptor
|
|
| Salbutamol adipate |
|
|
|
| Org 6906 |
α2-adrenergic receptor, pKi: 6.5
|
|
|
| Clorprenaline-d7 |
|
|
|
| CHIR-2279 |
α1-adrenergic receptor, Ki: 5 nM
|
|
|
| L-748328 |
|
β3 adrenoceptor, Ki: 3.7 nM
|
|
| L-770644 |
|
Beta-3 adrenergic receptor, EC50: 13 nM
|
|
| Cafedrine-theodrenaline |
|
|
|
| Etoperidone hydrochloride |
α1-adrenergic receptor, Kd: 38 nM
α2-adrenergic receptor, Kd: 570 nM
|
|
|
| Cicloprolol hydrochloride |
|
|
|
| Pargolol hydrochloride |
|
|
|
| Ko-3290 |
|
|
|
| Tasipimidine |
Alpha-2A adrenergic receptor
|
|
|
| Ridazolol |
|
Beta-1 adrenergic receptor
|
|
| R 47 243 |
|
|
|
| Clozapine hydrochloride |
α2-adrenergic receptor, Ki: 51 nM
|
|
|
| Esmolol |
|
|
|
| LY 344864 hydrochloride |
rat α1-adrenergic receptor, Ki: 5.06 μM
rat α2-adrenergic receptor, Ki: 3.69 μM
|
|
|
| L-771688 |
|
|
99.46% |
| Midaglizole hydrochloride |
|
|
99.67% |
| α1 adrenoceptor-MO-1 |
|
|
|
| Epanolol |
|
|
|
| Benzquinamide |
|
|
|
| Fenmetozole Tosylate |
|
|
|
